Intelligence · Patents
Patents expiring in 2041
Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.
- Patents
- 2,000
Quick answer
2,000 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11072592
Small molecules that enable cartilage rejuvenation
granted -
US 11072600
Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
granted -
US 11072636
Peptide for inhibiting angiogenesis and use thereof
granted -
US 11072594
Trioxolane agents
granted -
US 11072598
Somatostatin modulators and uses thereof
granted -
US 11072606
Compositions and methods for treating diseases and conditions
granted -
US 11072629
Reprogramming of cellular adhesion
granted -
US 11072656
Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof
granted -
US 11072794
Compositions and their uses directed to huntingtin
granted -
US 11072581
N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors
granted -
US 11073523
Method for differentially diagnosing ACTH-dependent Cushing's syndrome
granted -
US 11072792
Materials and methods for treatment of usher syndrome type 2A
granted -
US 11072618
Compounds, compositions and methods
granted -
US 11071784
Biodegradable lipids for the delivery of active agents
granted -
US 11071749
Oligonucleotide analogues targeting human LMNA
granted -
US 11071727
Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
granted -
US 11071742
Compositions for improving cell viability and methods of use thereof
granted -
US 11071729
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
granted -
US 11071755
Materials and methods for engineering cells and uses thereof in immuno-oncology
granted -
US 11071759
Methods for treating ulcerative colitis
granted -
US 11071782
Method of filling a container with no headspace
granted -
US 11071780
Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
granted -
US 11071781
Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
granted -
US 11071787
Topiramate compositions and methods of making and using the same
granted -
US 11071728
Treatment of schizophrenia
granted -
US 11071778
Combination product for use in tumor vaccination
granted -
CA 3162611
COMPLEXES DE FER ET SELS DE CEUX-CI UTILISES EN TANT QU'AGENTS DE CONTRASTE POUR IRM
granted -
US 11078289
Cancer treatment
granted -
US 11078491
Vaccines against Zika virus based on Zika structure proteins
granted -
US 11078295
Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases
granted -
US 11078286
Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
granted -
US 11078266
Anti-human IL-3 antibodies, their use in treatment of a disease or malfunction associated with elevated expression or levels of IL-3, and their use in a method to detect human IL-3
granted -
US 11078252
T-cell receptor
granted -
US 11078201
Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists
granted -
US 11077178
Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use
granted -
US 11077109
Compounds having antibacterial activity and methods of use
granted -
US 11077077
Therapeutic compounds, formulations, and uses thereof
granted -
US 11077057
Polymer-grafted nanobins
granted -
US 11076599
Antimicrobial coating comprising chalcogenide nano-particles capped by chitosan
granted -
US 11077068
Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
granted -
US 11077072
Binge behavior regulators
granted -
US 11077090
Compounds and compositions and uses thereof
granted -
US 11077101
Compounds and methods of use
granted -
US 11078170
Cyclic sulfamide compounds and methods of using same
granted -
US 11077078
Compositions and methods for the treatment of cancer
granted -
US 11077079
GHB formulation and method for its manufacture
granted -
US 11077108
Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition
granted -
US 11077117
Pharmaceutical compositions comprising meloxicam
granted
Frequently asked questions
How many pharma patents expire in 2041?
2,000 published patents in our USPTO index have expiration dates falling in calendar year 2041.